Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
06/09Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
CI
06/01SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
05/31OMEROS : Announces preliminary results from additional critically ill covid-19 p..
AQ
05/28OMEROS : Unveils Initial Results From Narsoplimab Treatment of Additional 'Criti..
MT
05/28OMEROS : Announces Preliminary Results from Additional Critically Ill COVID-19 P..
BU
05/28Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 ..
CI
05/20OMEROS CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/20OMEROS' : Biologics License Application Review Period for Narsoplimab Extended b..
MT
05/20OMEROS : Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
BU
05/20Omeros Corporation Announces Extension of U.S. Food and Drug Administration R..
CI
05/14OMEROS' : Narsoplimab pivotal trial data to be shared as an oral presentation at..
AQ
05/13OMEROS : rsquo; Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentat..
BU
05/13Omeros Corporation Announces Data on Organ Function Improvement from Omeros’ ..
CI
05/12OMEROS : Reports First Quarter 2021 Financial Results (Form 8-K)
PU
05/10OMEROS : Q1 Earnings Snapshot
AQ
05/10OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
05/10Omeros Corporation Reports Earnings Results for the First Quarter Ended March..
CI
05/10OMEROS CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
05/10OMEROS CORPORATION : Reports First Quarter 2021 Financial Results
BU
05/05OMEROS CORPORATION : to Announce First Quarter Financial Results on May 10, 2021
BU
05/04OMEROS CORPORATION : Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis a..
BU
05/04Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis ..
CI
04/26OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy R..
MT
03/23OMEROS : Quantum Leap Dose First Patients With Narsoplimab in COVID-19 Trial
MT
03/23OMEROS : and Quantum Leap Announce First Patients Dosed with Narsoplimab in the ..
BU
03/23Omeros and Quantum Leap Announces First Patients Dosed with Narsoplimab in th..
CI
03/01OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
03/01OMEROS : 4Q Earnings Snapshot
AQ
03/01OMEROS CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
03/01OMEROS : Q4 Loss Widens As Revenue Tumbles
MT
03/01Omeros Corporation Reports Earnings Results for the Full Year Ended December ..
CI
03/01OMEROS CORPORATION : Reports Fourth Quarter and Year-End 2020 Financial Results
BU
02/25OMEROS CORPORATION : to Announce Fourth Quarter and Year-End Financial Results o..
BU
02/01OMEROS : UBS Starts Omeros at Buy With $25 Price Target
MT
01/26OMEROS : Hires Nadia Dac as Chief Commercial Officer
BU
01/26Omeros Corporation Appoints Nadia Dac as Its Chief Commercial Officer
CI
01/20OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy R..
MT
01/20OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral..
MT
01/20OMEROS CORPORATION : - Biologics License Application for Narsoplimab in HSCT-TMA..
AQ
01/19OMEROS' : Biologics License Application for Blood Vessel Damage Treatment Candid..
MT
01/19OMEROS : Biologics License Application for Narsoplimab in HSCT-TMA Accepted for ..
BU
01/19Omeros Corporation Announces Biologics License Application for Narsoplimab in..
CI
01/11OMEROS : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating
MT
2020OMEROS : CMS Confirms Continued Separate Payment for Omeros FDA-Approved OMIDRIA..
AQ
2020OMEROS : Gets Medicare Nod For Surgery Drug Omidira Pass-Through Billing Status ..
MT
2020OMEROS : CMS Confirms Continued Separate Payment for Omeros' FDA-Approved OMIDRI..
BU
2020Omeros Corporation Announces Centers for Medicare & Medicaid Services Confirm..
CI
2020OMEROS : Submits its Biologics License Application to U.S. FDA for Narsoplimab i..
AQ
2020OMEROS : Submits Biologics License Application to US FDA for Narsoplimab; Shares..
MT
2020OMEROS : Submits its Biologics License Application to U.S. FDA for Narsoplimab i..
BU
2020Omeros Corporation Submits its Biologics License Application to U.S. FDA for ..
CI
2020OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral..
MT
2020OMEROS : 3Q Earnings Snapshot
AQ
2020OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
2020Omeros Corporation Reports Earnings Results for the Third Quarter Ended Septe..
CI
2020OMEROS : Earnings Flash (OMER) OMEROS CORPORATION Reports Q3 EPS $-0.34, vs. Str..
MT
2020OMEROS CORP : Results of Operations and Financial Condition, Financial Statement..
AQ
2020OMEROS CORPORATION : Reports Third Quarter 2020 Financial Results
BU
2020OMEROS CORPORATION : to Announce Third Quarter Financial Results on November 9, ..
BU
2020OMEROS : Participates in Investor Conference Focused on COVID-19 Therapeutics in..
AQ
2020OMEROS : Participates in Investor Conference Focused on COVID-19 Therapeutics in..
BU
2020OMEROS : Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Tri..
AQ
2020OMEROS : Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Tri..
BU
2020Omeros Corporation Reports Final Efficacy and Safety Data from the Narsoplima..
CI
1  2  3  4  5  6  7  8Next
Upcoming event on OMEROS CORPORATION
08/10/21